Related News
Home 禄 Business 禄 Manufacturing
BMS expects to double pharmaceutical sales in China
By Ding Yining |
February 29, 2012, Wednesday
|
Online Edition
Online Edition
BIOPHARMACEUTICAL company Bristol-Myers Squibb today said it expects its China's sales to grow by 27 percent this year, double the growth in 2011, based on strong demand for its key hepatitis and diabetes products.
Last year, BMS's sales in China added 13 percent year on year, higher than its global growth pace of 9 percent.
"We plan to introduce at least two new prescription drugs to the Chinese market this year and focus on getting more new innovative products registered in China," Jean-Christophe Pointeau, president of BMS China, said in an interview today.
By 2016, the company is expected to launch another three new drugs in the Chinese market to grab a bigger market share.
Pointeau said BMS China is accelerating its transformation into a biopharmaceutical company that specializes in four disease areas, namely hepatitis, cancer, diabetes and cardiovascular diseases.
The United States-based biopharmaceutical company has tied up with local pharmaceutical companies such as Simcere Pharmaceutical Group and Wuxi Apptec to co-develop compounds that have the potential to be turned into new drugs.
Last year, BMS's sales in China added 13 percent year on year, higher than its global growth pace of 9 percent.
"We plan to introduce at least two new prescription drugs to the Chinese market this year and focus on getting more new innovative products registered in China," Jean-Christophe Pointeau, president of BMS China, said in an interview today.
By 2016, the company is expected to launch another three new drugs in the Chinese market to grab a bigger market share.
Pointeau said BMS China is accelerating its transformation into a biopharmaceutical company that specializes in four disease areas, namely hepatitis, cancer, diabetes and cardiovascular diseases.
The United States-based biopharmaceutical company has tied up with local pharmaceutical companies such as Simcere Pharmaceutical Group and Wuxi Apptec to co-develop compounds that have the potential to be turned into new drugs.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
